Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and ISHWARIA MOHAN SUBBIAH.
Connection Strength
1.851
-
Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol. 2015; 11(1):1-4.
Score: 0.525
-
Bringing wearable devices into oncology practice: fitting smart technology in the clinic. Discov Med. 2018 12; 26(145):261-270.
Score: 0.172
-
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848.
Score: 0.167
-
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769.
Score: 0.163
-
Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56.
Score: 0.156
-
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
Score: 0.138
-
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol. 2015 Jun 11; 8:66.
Score: 0.135
-
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer. 2015 Jul; 89(1):76-9.
Score: 0.134
-
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
Score: 0.114
-
Current update on gallbladder carcinoma. Abdom Radiol (NY). 2021 06; 46(6):2474-2489.
Score: 0.050
-
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers (Basel). 2020 Sep 16; 12(9).
Score: 0.049
-
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 09; 136:176-185.
Score: 0.048